Hot Features
RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeuti... RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 5500 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 3300 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 6375 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 7306 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 16102 | 1.08E-6 | CS |
| 156 | -0.014999 | -99.9933333333 | 0.015 | 0.1115 | 1.0E-6 | 596450 | 0.00785924 | CS |
| 260 | -0.014999 | -99.9933333333 | 0.015 | 0.1115 | 1.0E-6 | 596450 | 0.00785924 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.